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Poor functional antibody responses are present in nearly all patients with Chronic 1 
Lymphocytic Leukaemia, irrespective of total IgG concentration, and are associated with 2 
increased risk of infection 3 
 4 
 5 
Patients with chronic lymphocytic leukaemia (CLL) suffer considerable morbidity and 6 
mortality from infectious disease (Francis, et al 2006, Itala, et al 1992, Molica, et al 1993). 7 
This risk has been attributed to development of a secondary immunodeficiency which has 8 
a multi-factorial aetiology including the effects of the underlying disease, the age of 9 
patient and the influence of therapy (Thurmes, et al 2008). The most commonly 10 
recognized measure of immunodeficiency associated with CLL is 11 
hypogammaglobulinaemia, which becomes more common as the disease progresses 12 
(Ben-Bassat, et al 1979). 13 
 14 
Total IgG concentration is the most commonly used indicator of antibody deficiency but 15 
the magnitude of the humoral response against specific pathogens is also of considerable 16 
importance. Specific antibody deficiency refers to a state characterized by normal 17 
immunoglobulin concentrations but poor functional antibody levels and recurrent 18 
infections.  19 
 20 
We undertook a cross sectional study to examine the incidence of specific antibody 21 
deficiency in 56 patients with CLL over 3 weeks at Queen Elizabeth Hospital Birmingham 22 
and Birmingham Heartlands Hospital Hematology clinics in June 2013. Clinical data was 23 
obtained from electronic records. Vaccination history was sourced from 53 of the 56 24 
patients from primary care records. 25 
 26 
IgG antibody levels to 19 vaccine antigens were examined for evidence of specific 27 
antibody deficiency using a 19plex luminex assay. This measured 12 pneumococcal (Pn) 28 
polysaccharides (serotypes 1,3,4,5,6B,7F,9V,14,18C,19A,19F,23F), four meningococcal 29 
polysaccharides (serogroups Men A,C,W,Y), Haemophilus influenza–b (Hib), tetanus toxoid 30 
and diphtheria toxoid. Results were considered protective at values recommended from WHO 31 
(Pn ≥0.35μg/ml in 8/12 serotypes, Men ≥2μg/ml, tetanus ≥0.1IU/ml, diphtheria ≥0.1IU/ml, 32 
Hib≥1μg/ml).  33 
 34 
As reported in previous studies, a high incidence of infection was observed even in 35 
patients with early stage disease {Hamblin, 2008}. Thirty one patients (55%) had one or 36 
more documented infections and 15 patients (27%) had at least one hospital admission 37 
due to infection. Within the total cohort, the median IgG concentration was 7.6g/l (IQR. 38 
5.08-9.01) and 22 (39%) of patients had IgG concentrations below the normal lower limit 39 
of 6g/L. Hypogammaglobulinaemia was associated with significantly more hospital-40 
recorded infection (p=0.036). Amongst untreated patients with Binet stage A disease who 41 
are on ‘watch and wait’ management, those with one or more infection(s) had 42 
significantly lower IgG concentrations than patients who did not suffer infections (6.3 g/l 43 
v 9.0 g/l, p = 0.037). Patients with an IgG <6g/l at diagnosis also had a shorter time to first 44 
infection (p=0.01) and more commonly reported symptoms of cough (p = 0.05) and 45 
sputum production (p = 0.05).  46 
 47 
There were significantly lower functional antibody concentrations against 16 of the 19 48 
serotypes measured in CLL patients compared to an age-matched control group of 162 49 
unvaccinated healthy patients with a median age of 74.6 years (66.2-83.0) (Phillips, et al 50 
2006). For pneumococcal serotypes, protective levels were demonstrated in only 3 of 12 51 
serotypes compared with 9 out of 12 within the healthy control group. This indicates 52 
that the specific antibody deficiency seen in CLL is related to the disease and not simply 53 
a reflection of immunosenescence secondary to age.  Patients with IgG<6g/l had a more 54 
marked specific antibody deficiency and were protected against a median of only 2 55 
serotypes compared to 5 in those with IgG within the normal range (p=0.002). However, 56 
79% (27/34) of patients with a normal IgG concentration still had suboptimal specific 57 
antibody responses to pneumococcus, demonstrating that IgG testing alone is not 58 
sufficient to identify patients at risk of infection (Figure 1). Similarly, specific antibodies 59 
against the other antigens tested were also found to be below protective levels in 60 
patients with a normal IgG; Men A: n=13 (38%), Men C: n=33 (97%); Men W n=28 61 
(82%), Men Y n= 32 (94%), Tetanus n=13 (38%), Diphtheria n= 26 (96%) and Hib n=14 62 
(41%).  63 
 64 
Current BCSH guidelines for the management of B-CLL recommend screening for total 65 
immunoglobulin levels as a means of identifying patients at risk of infection. Specific 66 
antibody testing is currently recommended only after vaccination as a means to assess 67 
immune response (Oscier, et al 2012). However, this strategy will fail to identify those 68 
patients with a normal IgG that have poor functional antibody concentrations. This has 69 
clinical importance as functional antibody concentration was found to be lower against 70 
all pneumococcal serotypes in patients with a history of infection (p=0.04). 71 
 72 
Surprisingly, despite the average age of the cohort being above 65 years, and with an 73 
underlying diagnosis of CLL, only 74% of patients had been vaccinated against 74 
Pneumococcus. 3 patients received Prevenar13 and the remainder had been given 75 
Pneumovax23. This suggests that a more robust system of vaccination is required with 76 
clear guidelines on whether this should occur in primary or secondary care. At the time 77 
of study the Joint Committee on Vaccination and Immunisation (JCVI) had recently 78 
changed their guidance for haematological malignancy and now recommend that 79 
patients should be immunized with the conjugated vaccine Prevenar13 followed, at least 80 
2 months later, by the previously recommended vaccine Pneumovax23. This study 81 
supports this decision in that we found patients who had received Pneumovax23 82 
polysaccharide vaccine (n= 37) had protective levels against only 2 of 12 compared with 83 
4 of 12 pneumococcal serotypes for unvaccinated patients.  The time from vaccination 84 
did not affect antibody concentrations. One study has found that the use of a single dose 85 
of Prevenar13 yields protective antibodies in 47% in CLL patients at 6 weeks (Sinisalo, 86 
et al 2007). To achieve higher rates of protection it may be necessary to utilize 87 
other vaccine schedules such as booster doses, as is routinely recommended in 88 
infants (Jodar, et al 2003, Rennels, et al 1998). In adult HIV patients, response 89 
rates almost double in those who received a second Prevenar vaccination 90 
(response rate 32% for one vaccine; 63.6% in those receiving a further booster 91 
dose) (Lu, et al 2014). A further consideration is the appropriate dose in patients 92 
with immunodeficiency; Jackson et al examined a dose range of Prevenar 93 
vaccination finding that a double dose was more immunogenic in an elderly 94 
population with presumed immunosenescence (Jackson, et al 2007).  Evidence for 95 
alternative schedules in adults is limited and is the focus of ongoing research in 96 
haematological patients with secondary immunodeficiency.  97 
 98 
This cross sectional study highlights the importance of investigating for antibody 99 
deficiency even in the early stages of CLL and supports a strategy of examining both 100 
whole and specific antibodies. Vaccination status should be checked on an annual basis. 101 
Enhanced vaccine regimens and additional strategies, such as prophylactic antibiotics or 102 
immunoglobulin replacement therapy, are required to reduce the high morbidity and 103 
mortality of infection in CLL. 104 
 105 
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